# PRIMe-STAR (NCT07150806)

> RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07150806
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Joshua Palmer
- Conditions: Recurrent Meningioma
- Interventions: Actinium Ac 225 DOTATATE RYZ101; Biospecimen Collection; Computed Tomography; Echocardiography Test; Gallium Ga 68-DOTATATE; L-lysine/L-arginine-containing Amino Acid; Magnetic Resonance Imaging; Multigated Acquisition Scan; Positron Emission Tomography; Somatostatin Receptor Positron Emission Tomography
- Enrollment: 30
- Primary outcome: Progression free survival (PFS)

## Indexed commentary on PRIMe-STAR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=prime-star-nct07150806